Cytokine modulated model growth inhibitory mechanisms

细胞因子调节模型生长抑制机制

基本信息

  • 批准号:
    7728141
  • 负责人:
  • 金额:
    $ 28.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-05-07 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cytokines regulate neoplastic cell growth in vivo either by inducing the expression of growth suppressor genes in tumors or by mounting an immune response against them. The interferon family of cytokines regulates several physiologic responses such as antiviral, antitumor, and immune functions. By interacting with other cytokines, IFNs become an integral part of a large of intercellular signaling network that promotes anti-tumor and anti-pathogen surveillance system in vivo. In an earlier study, we demonstrated that the IFN-induced anti-tumor actions, especially apoptosis, could be synergistically augmented by all-trans retinoic acid (RA). This vitamin-A metabolite by itself acts as a growth inhibitor in many experimental and clinical models. Some clinical studies also demonstrated the potent tumor inhibitory effects of IFN/RA. We hypothesized that IFN/RA employs novel gene products for suppressing tumor growth. To identify the critical molecules involved in IFN/RA-induced apoptosis, we have used a genetic strategy and identified several Genes associated with Retinoid-Interferon-induced Mortality (GRIM). One such novel gene product, GRIM-19, suppresses growth via apoptosis. Previous studies by us and others showed that its activity suppressed by DNA viral oncoproteins and some cellular proteins. These observations indicate its potent anti-oncogenic characteristics. During the last funding period we have shown that GRIM-19 binds to Signal Transducer and Activator of Transcription 3 (STAT3) and suppresses its growth promoting action using cell line models. STAT3, a dormant cytokine-regulated transcription factor, is constitutively activated in a number of human tumors by oncogenic signals. STAT3 activity is regulated in normal cells by feedback inhibitors. Persistent STAT3 activity promotes survival, proliferation, metastasis of tumor cells by stimulating the expression of various cellular genes involved in those responses. Although oncogenic activation of STAT3 is an important step, we suggest that loss or inactivation of its inhibitors may also play a critical step in this process prior to the promotion of tumor growth. In preliminary studies, we showed that GRIM-19 suppress constitutive STAT3- induced tumor growth and metastasis using xenograft models. Consistent with these, we observed a loss of expression and mutations in GRIM-19 in several primary human tumors, which correlated with a strong upregulation of STAT3-inducible genes and promotion of cell growth. In this renewal application, we will investigate the biological relevance of GRIM-19 to tumor growth in vivo using knockout and transgenic mice. We will investigate the impact of grim19 mutations (found in primary tumors) on oncogene-induced tumor growth promotion using in vitro and in vivo models. Although a deregulation of STAT3 is known in many tumors, the molecular mechanisms of its deregulation, specifically the role of its inhibitors in tumor development are poorly studied. The studies proposed in this application will define how tumor- specific dysfunctions in GRIM-19 affect the functioning of this new growth regulatory pathway. PUBLIC HEALTH RELEVANCE: Cases of Squamous cell carcinoma (SCC), a form of non-melanoma skin cancer (NMSC), are on the rise, with over a million new cases annually in U.S.A. Persistently activated STAT3 is found in many SCCs and other cancers, which correlates with an aggressive growth of tumors. This proposal for the first time will define the importance of GRIM-19, an inhibitor of STAT3, in tumor suppression. The information gained from these studies will be useful in developing designer therapies for treating SCCs and other cancers, where abnormal STAT3 activities are observed.
描述(由申请人提供):细胞因子通过诱导肿瘤中生长抑制基因的表达或通过建立针对它们的免疫应答来调节体内肿瘤细胞生长。干扰素家族的细胞因子调节几种生理反应,如抗病毒,抗肿瘤和免疫功能。通过与其他细胞因子相互作用,IFN成为一个庞大的细胞间信号网络的组成部分,促进体内抗肿瘤和抗病原体监视系统。在早期的研究中,我们证明了干扰素诱导的抗肿瘤作用,特别是细胞凋亡,可以协同增强全反式维甲酸(RA)。这种维生素A代谢物本身在许多实验和临床模型中作为生长抑制剂。一些临床研究也证明了IFN/RA的有效的肿瘤抑制作用。我们假设IFN/RA采用新的基因产物来抑制肿瘤生长。为了鉴定参与IFN/RA诱导的细胞凋亡的关键分子,我们使用遗传策略并鉴定了与类维生素A干扰素诱导的死亡率(GRIM)相关的几个基因。一种这样的新基因产物GRIM-19通过凋亡抑制生长。我们和其他人的前期研究表明,它的活性受到DNA、病毒、癌蛋白和某些细胞蛋白的抑制。这些观察结果表明其有效的抗癌特性。在上一个资助期间,我们已经证明GRIM-19与信号转导和转录激活因子3(STAT 3)结合,并使用细胞系模型抑制其促生长作用。STAT 3是一种休眠的腺嘌呤调节的转录因子,在许多人类肿瘤中被致癌信号组成性激活。STAT 3活性在正常细胞中由反馈抑制剂调节。持续的STAT 3活性通过刺激参与这些反应的各种细胞基因的表达来促进肿瘤细胞的存活、增殖、转移。虽然STAT 3的致癌激活是一个重要步骤,但我们认为其抑制剂的丢失或失活也可能在促进肿瘤生长之前在此过程中发挥关键作用。在初步研究中,我们使用异种移植模型显示GRIM-19抑制组成型STAT 3诱导的肿瘤生长和转移。与这些一致,我们观察到在几种原发性人类肿瘤中GRIM-19的表达丧失和突变,这与STAT 3诱导基因的强烈上调和细胞生长的促进相关。在这次更新申请中,我们将使用基因敲除和转基因小鼠研究GRIM-19与体内肿瘤生长的生物学相关性。我们将使用体外和体内模型研究grim 19突变(在原发性肿瘤中发现)对癌基因诱导的肿瘤生长促进的影响。虽然STAT 3的失调在许多肿瘤中是已知的,但其失调的分子机制,特别是其抑制剂在肿瘤发展中的作用研究很少。本申请中提出的研究将定义GRIM-19中的肿瘤特异性功能障碍如何影响这种新的生长调节途径的功能。公共卫生相关性:鳞状细胞癌(SCC),一种非黑色素瘤皮肤癌(NMSC)的病例正在增加,在美国每年有超过一百万的新病例。在许多SCC和其他癌症中发现了持续激活的STAT 3,这与肿瘤的侵袭性生长相关。这一提议将首次定义STAT 3抑制剂GRIM-19在肿瘤抑制中的重要性。从这些研究中获得的信息将有助于开发用于治疗SCC和其他癌症的设计师疗法,其中观察到异常STAT 3活性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DHAN V. KALVAKOLANU其他文献

DHAN V. KALVAKOLANU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DHAN V. KALVAKOLANU', 18)}}的其他基金

GRIM19 for head and neck cancer therapy
GRIM19 用于头颈癌治疗
  • 批准号:
    9408784
  • 财政年份:
    2017
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated novel growth inhibitory mechanisms
细胞因子调节的新型生长抑制机制
  • 批准号:
    7406846
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated model growth inhibitory mechanisms
细胞因子调节模型生长抑制机制
  • 批准号:
    8257946
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated model growth inhibitory mechanisms
细胞因子调节模型生长抑制机制
  • 批准号:
    7840509
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated novel growth inhibitory mechanisms
细胞因子调节的新型生长抑制机制
  • 批准号:
    7033005
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated novel growth inhibitory mechanisms
细胞因子调节的新型生长抑制机制
  • 批准号:
    7228908
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated model growth inhibitory mechanisms
细胞因子调节模型生长抑制机制
  • 批准号:
    8065508
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated model growth inhibitory mechanisms
细胞因子调节模型生长抑制机制
  • 批准号:
    8471659
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated novel growth inhibitory mechanisms
细胞因子调节的新型生长抑制机制
  • 批准号:
    6893451
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:
Cytokine modulated novel growth inhibitory mechanisms
细胞因子调节的新型生长抑制机制
  • 批准号:
    6719437
  • 财政年份:
    2004
  • 资助金额:
    $ 28.1万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 28.1万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 28.1万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 28.1万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 28.1万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 28.1万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 28.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 28.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了